Effect of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin on Forearm Endothelial Function in Diabetics

Effect of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin on Forearm Endothelial Function in Diabetics - EDPI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220223

Enrollment

Registered

2015-08-21

Start date

2015-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic patient

Interventions

Intervention type:DRUG Name of intervention:Open random study Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application:ORAL Dose per administration:20mg 20

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic patients diabetic patients with HbA1c>7.0% (NGSP)

Exclusion criteria

Exclusion criteria: 1. Contraindication of Teneligliptin 2. complicated with severe cardiac,renal and liver diseases 3. The patients whom the investigating physician disagree with enrollment

Design outcomes

Primary

Measure	Time frame
endothelial function	—

Secondary

Measure	Time frame
Effect on plasma glucose levels	—

Countries

Japan

Contacts

Public ContactBonpei Takase

National defense medical college

takaseb-18@ndmc.ac.jp+81-4-2995-1511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026